Tracking clinical resources for coronavirus disease 2019

Curr Opin Rheumatol. 2020 Sep;32(5):441-448. doi: 10.1097/BOR.0000000000000724.


Purpose of review: Assimilating and disseminating information during the novel coronavirus disease 2019 (COVID-19) has been challenging. The purpose of this review is to identify specific threats to the validity of the COVID-19 literature and to recommend resources for practicing rheumatologists and their patients.

Recent findings: The COVID-19 literature has rapidly expanded and includes 17 998 publications through May of 2020, 1543 of which also address rheumatic disease-related topics. Specific obstacles to acquiring high-quality information have arisen, including 'pandemic research exceptionalism' and a 'parallel pandemic' of misinformation. Unique challenges to rheumatologists include specific interest in antirheumatic disease therapies and a paucity of rheumatology-specific information. Patients with rheumatic diseases have faced shortages of critical medications and a lack of information tailored to their health conditions and medications.

Summary: We recommend rheumatologists develop a system to acquire high-quality information and offer guiding principles for triaging specific resources, which include relevance, accessibility, credibility, timeliness, and trustworthiness. The same principles can be applied to selecting patient oriented resources. Specific trustworthy resources are recommended.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections* / complications
  • Humans
  • Pandemics*
  • Patient Selection
  • Pneumonia, Viral* / complications
  • Rheumatic Diseases* / complications
  • Rheumatic Diseases* / drug therapy
  • SARS-CoV-2


  • Antirheumatic Agents